Lineage Cell Therapeutics, Inc. (LCTX) Revenue 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.
$14.6MFY2025 · since FY2016: $5.9M → $14.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $14.6M | +53.2% |
| FY2024 | $9.5M | +6.2% |
| FY2023 | $8.9M | -39.2% |
| FY2022 | $14.7M | +238.7% |
| FY2021 | $4.3M | +137.7% |
| FY2020 | $1.8M | -48.1% |
| FY2019 | $3.5M | -29.5% |
| FY2018 | $5.0M | +44.2% |
| FY2017 | $3.5M | -41.6% |
| FY2016 | $5.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More LCTX financial trends
LCTX Net incomeLCTX Net marginLCTX Gross profitLCTX Gross marginLCTX Operating incomeLCTX Operating marginLCTX Operating cash flowLCTX Free cash flowLCTX Capital expendituresLCTX Return on equityLCTX Stock buybacksLCTX Dividends paidLCTX Total assetsLCTX Total liabilitiesLCTX Shareholders’ equityLCTX overview →